{"id":514358,"date":"2021-07-19T07:33:18","date_gmt":"2021-07-19T11:33:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/"},"modified":"2021-07-19T07:33:18","modified_gmt":"2021-07-19T11:33:18","slug":"contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/","title":{"rendered":"ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">YONKERS, N.Y., July  19, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"http:\/\/www.contrafect.com\" rel=\"nofollow noopener\" target=\"_blank\"><strong>ContraFect Corporation<\/strong><\/a><strong>(Nasdaq: CFRX)<\/strong>, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the publication of two manuscripts that demonstrate the potent <em>in vivo<\/em> activity of CF-296, a novel engineered lysin agent with potent bactericidal and anti-biofilm activity against <em>Staphylococcus aureus <\/em>(<em>Staph aureus<\/em>), a life-threatening pathogen.<\/p>\n<p align=\"justify\">\u201cThis new research data demonstrates the potential of CF-296, our novel engineered variant of exebacase, our lead lysin product candidate currently in an ongoing Phase 3 clinical trial. As we continue to develop the profile of this product candidate, we are evaluating multiple potential indications for clinical development, including <em>Staph aureus<\/em> osteomyelitis and prosthetic joint infections, particularly difficult-to-treat, potentially disabling infections, where novel treatments are greatly needed,\u201d said Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development at ContraFect.<\/p>\n<p align=\"justify\">The manuscript published in <a href=\"https:\/\/journals.asm.org\/doi\/abs\/10.1128\/aac.00117-21\" rel=\"nofollow noopener\" target=\"_blank\">Antimicrobial Agents and Chemotherapy<\/a>, a leading peer-reviewed journal dedicated to the study of infectious diseases, presents laboratory data from a study of CF-296 in a preclinical rodent model of acute methicillin-resistant <em>Staph aureus<\/em> (MRSA) osteomyelitis. The analysis of bone samples demonstrated that CF-296 has potent anti-staphylococcal activity and, when used with daptomycin, is active and well tolerated in MRSA acute osteomyelitis.<\/p>\n<p align=\"justify\">In a second manuscript published in the peer-reviewed <a href=\"https:\/\/academic.oup.com\/jac\/advance-article-abstract\/doi\/10.1093\/jac\/dkab206\/6314896?redirectedFrom=fulltext\" rel=\"nofollow noopener\" target=\"_blank\">Journal of Antimicrobial Chemotherapy<\/a>, CF-296 demonstrated the efficacy of CF-296, both as a mono therapy and in addition to standard-of-care antibiotics, in a preclinical murine <em>Staph aureus<\/em> infection model. Of note, the addition of CF-296 to both daptomycin or vancomycin resulted in significantly enhanced antibacterial activity in the model, relative to the activity of these standard-of-care antibiotics alone.<\/p>\n<p align=\"justify\">ContraFect continues to evaluate CF-296 in further preclinical studies and the potential for future clinical development. CF-296 was developed by ContraFect and the Company is actively pursuing global rights to this investigational development candidate.<\/p>\n<p>\n        <strong>About ContraFect:<\/strong>\n      <\/p>\n<p align=\"justify\">ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including <em>P. aeruginosa, Acinetobacter baumannii,<\/em> and <em>Enterobacter<\/em> species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and <em>P. aeruginosa<\/em>, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of <em>Staph aureus<\/em> bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics in adult patients.\u00a0\u00a0<\/p>\n<p>Follow ContraFect on Twitter <a href=\"https:\/\/twitter.com\/ContraFectCorp\" rel=\"nofollow noopener\" target=\"_blank\">@ContraFectCorp<\/a> and <a href=\"https:\/\/www.linkedin.com\/company\/contrafect-corp\/\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains, and our officers and representatives may make from time to time, \u201cforward-looking statements\u201d within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as \u201cprojects,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201cpromise\u201d or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding: the CF-296 publications, study results and development and ownership rights, ContraFect\u2019s ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, whether ContraFect will address life-threatening infections using its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect\u2019s lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and <em>P. aeruginosa<\/em>. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect\u2019s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect\u2019s control, including the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect\u2019s product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection and other important risks detailed under the caption \u201cRisk Factors\u201d in ContraFect&#8217;s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n<p>\n        <strong>Investor Relations Contacts<\/strong>\n      <\/p>\n<p>Michael Messinger<br \/>ContraFect Corporation<br \/><a href=\"mailto:mmessinger@contrafect.com\" rel=\"nofollow noopener\" target=\"_blank\">mmessinger@contrafect.com<\/a><\/p>\n<p>Carlo Tanzi, Ph.D.<br \/>Kendall Investor Relations<br \/><a href=\"mailto:ctanzi@kendallinvestorrelations.com\" rel=\"nofollow noopener\" target=\"_blank\">ctanzi@kendallinvestorrelations.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjU0NiM0MzAyOTQxIzIwOTE5NDg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/5184a116-cd5c-4ffa-8695-aa41dd9cb65f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) &#8212; ContraFect Corporation(Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the publication of two manuscripts that demonstrate the potent in vivo activity of CF-296, a novel engineered lysin agent with potent bactericidal and anti-biofilm activity against Staphylococcus aureus (Staph aureus), a life-threatening pathogen. \u201cThis new research data demonstrates the potential of CF-296, our novel engineered variant of exebacase, our lead lysin product candidate currently in an ongoing Phase 3 clinical trial. As we continue to develop the profile of this product candidate, we are evaluating &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-514358","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) &#8212; ContraFect Corporation(Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the publication of two manuscripts that demonstrate the potent in vivo activity of CF-296, a novel engineered lysin agent with potent bactericidal and anti-biofilm activity against Staphylococcus aureus (Staph aureus), a life-threatening pathogen. \u201cThis new research data demonstrates the potential of CF-296, our novel engineered variant of exebacase, our lead lysin product candidate currently in an ongoing Phase 3 clinical trial. As we continue to develop the profile of this product candidate, we are evaluating &hellip; Continue reading &quot;ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-19T11:33:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjU0NiM0MzAyOTQxIzIwOTE5NDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity\",\"datePublished\":\"2021-07-19T11:33:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\\\/\"},\"wordCount\":1035,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MjU0NiM0MzAyOTQxIzIwOTE5NDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\\\/\",\"name\":\"ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MjU0NiM0MzAyOTQxIzIwOTE5NDg=\",\"datePublished\":\"2021-07-19T11:33:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MjU0NiM0MzAyOTQxIzIwOTE5NDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MjU0NiM0MzAyOTQxIzIwOTE5NDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/","og_locale":"en_US","og_type":"article","og_title":"ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity - Market Newsdesk","og_description":"YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) &#8212; ContraFect Corporation(Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the publication of two manuscripts that demonstrate the potent in vivo activity of CF-296, a novel engineered lysin agent with potent bactericidal and anti-biofilm activity against Staphylococcus aureus (Staph aureus), a life-threatening pathogen. \u201cThis new research data demonstrates the potential of CF-296, our novel engineered variant of exebacase, our lead lysin product candidate currently in an ongoing Phase 3 clinical trial. As we continue to develop the profile of this product candidate, we are evaluating &hellip; Continue reading \"ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-19T11:33:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjU0NiM0MzAyOTQxIzIwOTE5NDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity","datePublished":"2021-07-19T11:33:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/"},"wordCount":1035,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjU0NiM0MzAyOTQxIzIwOTE5NDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/","name":"ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjU0NiM0MzAyOTQxIzIwOTE5NDg=","datePublished":"2021-07-19T11:33:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjU0NiM0MzAyOTQxIzIwOTE5NDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjU0NiM0MzAyOTQxIzIwOTE5NDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-multiple-publications-on-cf-296-demonstrating-potent-in-vivo-antimicrobial-activity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/514358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=514358"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/514358\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=514358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=514358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=514358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}